Doreen Lugano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Doreen Lugano has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Laurence Routh
Department of Microbiology and Immunology, Scripps Research, La Jolla, USA
2 shared publications - Arnold Wasike Lambisia
KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
2 shared publications - Charles Nyaigoti Agoti
KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research
2 shared publications - James Nyagwange
Epidemiology and Demography Department, Kenya Medical Research Institute–Wellcome Trust Research Programme , Kilifi
2 shared publications - Samuel O. Oyola
International Livestock Research Institute
2 shared publications - Abdhalah Kasiira Ziraba
African Population and Health Research Center
1 shared publication
Latest Publications
- 6 November 2026
- Published by Cold Spring Harbor Laboratory in RNA
Uplifting RNA Science in Africa: A Call to Action
The 21st century has witnessed the emergence of an entire new class of therapeutic and prophylactic medicines based on RNA. These transformative advances have arisen from decades of fundamental and applied research efforts to understand, exploit, and modify the properties of RNA to improve lives and livelihoods for patients and broader societal stakeholders. However, the contributions of African scientists, businesses and policymakers to the RNA research ecosystem have been minimal. This, despite the opportunities for exploitation of RNA-based medicines in specific health issues endemic to the region, such as the neglected tropical diseases schistosomiasis, lymphatic filariasis and Buruli ulcer, as well as chronic respiratory disorders (asthma, chronic obstructive pulmonary disorder) that disproportionately impact low and middle countries. Here, we outline some of the challenges faced by the incipient RNA bioscience research community in Africa, which remains hindered by a deficiency of strategic vision and insufficient momentum, an underdeveloped culture of collaboration, and persistent constraints in resources and infrastructure. Overcoming these issues requires a re-imagining of how the global RNA research community and African scholars mobilise resources for co-production of RNA-related knowledge and innovation. Potential solutions include forging equitable partnerships with institutions in the Global North, strengthening local, regional, and transnational collaborative networks in RNA science, and developing grassroots platforms that expand RNA education, research training, and communitywide networking across Africa. Together, these approaches offer a pathway to build sustainable capacity, nurture scientific leadership, and accelerate the growth of the continent’s RNA bioscience ecosystem.
- 6 November 2026
- Published by Cold Spring Harbor Laboratory in RNA
Uplifting RNA Science in Africa: A Call to Action
The 21st century has witnessed the emergence of an entire new class of therapeutic and prophylactic medicines based on RNA. These transformative advances have arisen from decades of fundamental and applied research efforts to understand, exploit, and modify the properties of RNA to improve lives and livelihoods for patients and broader societal stakeholders. However, the contributions of African scientists, businesses and policymakers to the RNA research ecosystem have been minimal. This, despite the opportunities for exploitation of RNA-based medicines in specific health issues endemic to the region, such as the neglected tropical diseases schistosomiasis, lymphatic filariasis and Buruli ulcer, as well as chronic respiratory disorders (asthma, chronic obstructive pulmonary disorder) that disproportionately impact low and middle countries. Here, we outline some of the challenges faced by the incipient RNA bioscience research community in Africa, which remains hindered by a deficiency of strategic vision and insufficient momentum, an underdeveloped culture of collaboration, and persistent constraints in resources and infrastructure. Overcoming these issues requires a re-imagining of how the global RNA research community and African scholars mobilise resources for co-production of RNA-related knowledge and innovation. Potential solutions include forging equitable partnerships with institutions in the Global North, strengthening local, regional, and transnational collaborative networks in RNA science, and developing grassroots platforms that expand RNA education, research training, and communitywide networking across Africa. Together, these approaches offer a pathway to build sustainable capacity, nurture scientific leadership, and accelerate the growth of the continent’s RNA bioscience ecosystem.
- Open Access
Low Transmission of the Globally Dominant Recombinant SARS-CoV-2 XFG variant in Kenya, May-July 2025
Objective: The ongoing SARS-CoV-2 evolution has produced over 5,200 genetically distinct PANGO lineages whose epidemiological trajectories differ across regions. In early 2025, a new recombinant SARS-CoV-2 variant named XFG emerged, predominating in most global regions by June 2025. Here we describe XFG introduction and molecular epidemiological patterns in Kenya, May - July 2025. Results: Of 7,564 nasopharyngeal/oropharyngeal swabs sampled across three surveillance platforms (a community cohort and two outpatient ARI) and tested by quantitative PCR, only 23 (0.03%) were positive. From these, we recovered six near-complete genomes that mapped to PANGO lineages XFG.12, XFG.4.1, XFG.7 and XFG.21. The median age of the positive cases was 18 years (IQR 10.0–21.8) and presented mainly with runny nose (47.6%), cough (42.9%), sore throat (33.3%) and fever (33.3%). Phylogenetic analysis including 14 sequences from Nairobi deposited on GISAID suggested at least 13 introduction events of the XFG variant into Kenya. Amino acid differences were observed between the Kenyan XFG.12 and XFG.4.1 in the ORF1a (H45Y) and ORF1b (D1848X/Y) proteins respectively. We confirm introduction but limited transmission of the XFG variant in Kenya during May–July 2025. This observation underlines the importance of regional genomic surveillance for appropriate and optimized intervention design.
Open AccessLow Transmission of the Globally Dominant Recombinant SARS-CoV-2 XFG variant in Kenya, May-July 2025
Objective: The ongoing SARS-CoV-2 evolution has produced over 5,200 genetically distinct PANGO lineages whose epidemiological trajectories differ across regions. In early 2025, a new recombinant SARS-CoV-2 variant named XFG emerged, predominating in most global regions by June 2025. Here we describe XFG introduction and molecular epidemiological patterns in Kenya, May - July 2025. Results: Of 7,564 nasopharyngeal/oropharyngeal swabs sampled across three surveillance platforms (a community cohort and two outpatient ARI) and tested by quantitative PCR, only 23 (0.03%) were positive. From these, we recovered six near-complete genomes that mapped to PANGO lineages XFG.12, XFG.4.1, XFG.7 and XFG.21. The median age of the positive cases was 18 years (IQR 10.0–21.8) and presented mainly with runny nose (47.6%), cough (42.9%), sore throat (33.3%) and fever (33.3%). Phylogenetic analysis including 14 sequences from Nairobi deposited on GISAID suggested at least 13 introduction events of the XFG variant into Kenya. Amino acid differences were observed between the Kenyan XFG.12 and XFG.4.1 in the ORF1a (H45Y) and ORF1b (D1848X/Y) proteins respectively. We confirm introduction but limited transmission of the XFG variant in Kenya during May–July 2025. This observation underlines the importance of regional genomic surveillance for appropriate and optimized intervention design.
- Open Access
- 17 June 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (6) , e0048225
Characterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population
Vaccination is a key control measure of coronavirus disease 2019 by preventing severe effects of disease outcomes, reducing hospitalization rates and death, and increasing immunity. However, vaccination can affect the evolution and adaptation of SARS-CoV-2 largely through vaccine-induced immune pressure. Here, we investigated intrahost recombination and single nucleotide variations (iSNVs) on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome in non-vaccinated and vaccinated sequences from the Kenyan population to profile intrahost viral genetic evolution and adaptations driven by vaccine-induced immune pressure. We identified recombination hotspots in the S, N, and ORF1a/b genes and showed the genetic evolution landscape of SARS-CoV-2 by comparing within- and inter-wave recombination events from the beginning of the pandemic (June 2020 to December 2022) in Kenya. We further reveal differential expression of recombinant RNA species between vaccinated and non-vaccinated individuals and perform an in-depth analysis of iSNVs to identify and characterize the functional properties of non-synonymous mutations found in ORF-1 a/b, S, and N genes. Lastly, we detected a minority variant in non-vaccinated patients in Kenya, with an immune escape mutation S255F of the spike gene, and showed differential recombinant RNA species. Overall, this work identified unique in vivo mutations and intrahost recombination patterns in SARS-CoV-2, which could have significant implications for virus evolution, virulence, and immune escape. IMPORTANCE: The impact of vaccination on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic diversity in Kenya and much of Africa remains unknown. This can be attributed to lower sequencing rates; however, this information is relevant to improvement in vaccine and antiviral research. In this study, we investigated how vaccination and SARS-CoV-2 transmission waves affect intrahost non-homologous recombination and single nucleotide variations (iSNVs). We identified unique in vivo mutations and intrahost recombination patterns in SARS-CoV-2, which could have significant implications for virus evolution, virulence, and immune escape. We also demonstrate a methodology for studying genetic changes in a pathogen by a simultaneous analysis of both intrahost single nucleotide variations and recombination events. The study reveals the diversity of SARS-CoV-2 in Kenya and highlights the need for sustained genomic surveillance in Kenya and Africa to better understand how the virus evolves. Such surveillance ensures detection of drifts in evolution, allowing information for updates in vaccines, policy making, and containment of future variants of SARS-CoV-2.
- 17 June 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (6) , e0048225
Open AccessCharacterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population
Vaccination is a key control measure of coronavirus disease 2019 by preventing severe effects of disease outcomes, reducing hospitalization rates and death, and increasing immunity. However, vaccination can affect the evolution and adaptation of SARS-CoV-2 largely through vaccine-induced immune pressure. Here, we investigated intrahost recombination and single nucleotide variations (iSNVs) on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome in non-vaccinated and vaccinated sequences from the Kenyan population to profile intrahost viral genetic evolution and adaptations driven by vaccine-induced immune pressure. We identified recombination hotspots in the S, N, and ORF1a/b genes and showed the genetic evolution landscape of SARS-CoV-2 by comparing within- and inter-wave recombination events from the beginning of the pandemic (June 2020 to December 2022) in Kenya. We further reveal differential expression of recombinant RNA species between vaccinated and non-vaccinated individuals and perform an in-depth analysis of iSNVs to identify and characterize the functional properties of non-synonymous mutations found in ORF-1 a/b, S, and N genes. Lastly, we detected a minority variant in non-vaccinated patients in Kenya, with an immune escape mutation S255F of the spike gene, and showed differential recombinant RNA species. Overall, this work identified unique in vivo mutations and intrahost recombination patterns in SARS-CoV-2, which could have significant implications for virus evolution, virulence, and immune escape. IMPORTANCE: The impact of vaccination on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic diversity in Kenya and much of Africa remains unknown. This can be attributed to lower sequencing rates; however, this information is relevant to improvement in vaccine and antiviral research. In this study, we investigated how vaccination and SARS-CoV-2 transmission waves affect intrahost non-homologous recombination and single nucleotide variations (iSNVs). We identified unique in vivo mutations and intrahost recombination patterns in SARS-CoV-2, which could have significant implications for virus evolution, virulence, and immune escape. We also demonstrate a methodology for studying genetic changes in a pathogen by a simultaneous analysis of both intrahost single nucleotide variations and recombination events. The study reveals the diversity of SARS-CoV-2 in Kenya and highlights the need for sustained genomic surveillance in Kenya and Africa to better understand how the virus evolves. Such surveillance ensures detection of drifts in evolution, allowing information for updates in vaccines, policy making, and containment of future variants of SARS-CoV-2.
- Open Access
Characterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population
Vaccination is a key control measure of COVID-19 by preventing severe effects of disease outcomes, reducing hospitalization rates and death, and increasing immunity. However, vaccination can affect the evolution and adaptation of SARS-CoV-2, largely through vaccine-induced immune pressure. Here we investigated intrahost recombination and single nucleotide variations (iSNVs) on the SARS-CoV-2 genome in non-vaccinated and vaccinated sequences from the Kenyan population to profile intrahost viral genetic evolution and adaptations driven by vaccine-induced immune pressure. We identified recombination hotspots in the S, N, and ORF1a/b genes and showed the genetic evolution landscape of SARS-CoV-2 by comparing within-wave and inter-wave recombination events from the beginning of the pandemic (June 2020) to (December 2022) in Kenya. We further reveal differential expression of recombinant RNA species between vaccinated and non-vaccinated individuals and perform an in-depth analysis of iSNVs to identify and characterize the functional properties of non-synonymous mutations found in ORF-1 a/b, S, and N genes. Lastly, we detected a minority variant in non-vaccinated patients in Kenya, with an immune escape mutation S255F of the spike gene and showed differential recombinant RNA species. Overall, this work identified unique in vivo mutations and intrahost recombination patterns in SARS-CoV-2 which could have significant implications for virus evolution, virulence, and immune escape.
Open AccessCharacterization of SARS-CoV-2 intrahost genetic evolution in vaccinated and non-vaccinated patients from the Kenyan population
Vaccination is a key control measure of COVID-19 by preventing severe effects of disease outcomes, reducing hospitalization rates and death, and increasing immunity. However, vaccination can affect the evolution and adaptation of SARS-CoV-2, largely through vaccine-induced immune pressure. Here we investigated intrahost recombination and single nucleotide variations (iSNVs) on the SARS-CoV-2 genome in non-vaccinated and vaccinated sequences from the Kenyan population to profile intrahost viral genetic evolution and adaptations driven by vaccine-induced immune pressure. We identified recombination hotspots in the S, N, and ORF1a/b genes and showed the genetic evolution landscape of SARS-CoV-2 by comparing within-wave and inter-wave recombination events from the beginning of the pandemic (June 2020) to (December 2022) in Kenya. We further reveal differential expression of recombinant RNA species between vaccinated and non-vaccinated individuals and perform an in-depth analysis of iSNVs to identify and characterize the functional properties of non-synonymous mutations found in ORF-1 a/b, S, and N genes. Lastly, we detected a minority variant in non-vaccinated patients in Kenya, with an immune escape mutation S255F of the spike gene and showed differential recombinant RNA species. Overall, this work identified unique in vivo mutations and intrahost recombination patterns in SARS-CoV-2 which could have significant implications for virus evolution, virulence, and immune escape.
- Open Access
Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4, using samples from two health demographic surveillance systems in Kenya
Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing the new variants to escape the immunity previously raised by vaccination and/or infection by earlier variants of SARS-CoV-2. In this study, we investigated the neutralizing capacity of antibodies against emerging variants of interest circulating between May 2023 and March 2024 using sera from representative samples of the Kenyan population. From our genomics data, we identified the most prevalent Kenyan and global variants and performed pseudoviruses neutralization assays with the most recent SARS-CoV-2 variants. Our data show that antibodies from individuals in the general population in Kenya were less effective against the recent prevalent SARS-CoV-2 omicron variants (i.e. EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4) compared to the ancestral wildtype strain. Although there was increased neutralization following multiple doses of vaccine, antibodies from >40% of the vaccinated individuals did not neutralize the omicron variants, suggesting that individuals were susceptible to infection by these variants.
Open AccessEvaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4, using samples from two health demographic surveillance systems in Kenya
Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing the new variants to escape the immunity previously raised by vaccination and/or infection by earlier variants of SARS-CoV-2. In this study, we investigated the neutralizing capacity of antibodies against emerging variants of interest circulating between May 2023 and March 2024 using sera from representative samples of the Kenyan population. From our genomics data, we identified the most prevalent Kenyan and global variants and performed pseudoviruses neutralization assays with the most recent SARS-CoV-2 variants. Our data show that antibodies from individuals in the general population in Kenya were less effective against the recent prevalent SARS-CoV-2 omicron variants (i.e. EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4) compared to the ancestral wildtype strain. Although there was increased neutralization following multiple doses of vaccine, antibodies from >40% of the vaccinated individuals did not neutralize the omicron variants, suggesting that individuals were susceptible to infection by these variants.